9M 2023 Financial Overview

9M 2023: APPENDIX Vyepti: Phase III study for treatment of cluster headache, a crippling pain with few effective medications currently available Cluster headache affects approximately one in 1,000 people across the world These are severe attacks of one-sided pain in the head, much stronger than a normal headache Cluster Headaches are also known as "Suicide Headaches" due to the intensity of pain leading to frequent suicide ideation Duration Frequency 15-180 min 1-8 times a day 20-40 yrs. 1:1,000 Age of onset Prevalence Episodic/chronic ratio 6:1 Male/female ratio 4.3:1 CHRONICLE¹) phase III study to evaluate safety of eptinezumab in chronic Cluster Headache (CCH) Eptinezumab intravenous in ~125 patients with CCH • Primary endpoint: Number of participants with adverse events • Results show that patients with chronic cluster headache receiving open-label treatment with eptinezumab report reductions in attack frequency, pain severity, and improvement on patient global impression ALLEVIATE²) phase III study to evaluate eptinezumab in episodic Cluster Headache (eCH) ⚫ Eptinezumab intravenous in ~300 patients with eCH . . Primary endpoint: Change from baseline in number of weekly attacks (Weeks 1-2) • First patient, first visit (FPFV) commenced in December 2020 21 27 1) ClinicalTrials.gov Identifier: NCT05064397 2) NCT04688775 Lundbeck

View entire presentation